For Free Headlines Submit Your Email
Monday, June 30, 2025 21:13 GMT
The Sultanate’s three principal fuel marketing companies reported a dramatic decline in their net earnings for the first quarter of this year, attributable largely to the effects of a burgeoning economic downturn slump as well as to a general lockdown ordered by authorities with the aim of curbing the spread of the novel coronavirus. Shell Oman Marketing Company’s (SOMC) net profit after tax for the quarter ended March 31, 2020, dived 93% to RO 0.122,000 (US$317,500), down from RO 1.775 million (US$4.619 million) for the corresponding period in 2019, the company said in initial unaudited financial results published last month. Revenues dipped 2.2% to RO 117.9 million (US$306.839 million) this year, down from RO 120.5 million (US$313.606 million) for Q1 2019.Oman Oil Marketing Company (OOMCO), the biggest of the trio by market share, reported a 46.7% decrease in net profit after tax to RO 602,000 (US$1.566 million) this past quarter, down from RO 1.130 million (US$2.940 million) for the corresponding quarter of 2019. Total revenue of the group was lower by 6.8% at RO 131.752 million (US$342.890 million) in Q1 this year versus, RO 141.390 million (US$367.973 million) for Q1 2019.Rounding off the list, Al Maha Petroleum Products Marketing Co announced a steep 86% fall in net profit after tax for the first quarter at RO 137,000 (US$356,550), down from RO 980,000 (US$2.550 million) in Q1 2019. Revenue for the quarter also declined 10% to RO 100.459 million (US$261.449 million), down from RO 111.938 million (US$291.323 million) for the corresponding quarter of 2019.According to experts, the impacts are expected to be much more pronounced in the current second quarter following the adoption of full-blown pandemic mitigation measures, which have resulted in the curtailment of most local and international flights, while vehicular traffic has been reduced to a minimum. Motor and aviation fuels are mainstay revenue sources for fuel marketing firms in the Sultanate.